RHEACELL announces FDA approval for Phase 3 study in refractory, non-curable CVU
more
Stories about Genetik
Scantox Group acquires Gentronix, a world leader in genetic toxicology
Ejby, Denmark (ots/PRNewswire) - Today Scantox, together with its majority owner Impilo, finalized the acquisition of Gentronix Ltd, a UK based GLP compliant genetic toxicology Contract Research Organization ("CRO"). Gentronix, now integrated into Scantox Group, is well recognized for its high-quality genetic toxicology services and strong scientific engagement, with ...
moreTechnische Universität München
What gave the first molecules their stability?
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE New insights into the origins of life What gave the first molecules their stability? • Until now, it was unclear how complex molecules could survive in the primordial soup• Unstable RNA molecules are stabilized by double strands • RNAs may be able to form their own complementary strand The origins of life remain a major mystery. How were complex molecules able to form and ...
moreNew Study: Father's Diet Before Conception Influences Children's Health
morePress Release: Restless Legs Syndrome: Genetic Discoveries Advance Treatment and Risk Prediction
Researchers at Helmholtz Munich and the Technical University of Munich (TUM) together with international collaborators have conducted the largest genetic investigation of the restless legs syndrome to date. Their findings, ...
morePress release: Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK
Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK - Bio-Thera and STADA have reached an exclusive commercialization and license agreement for BAT2506, a biosimilar candidate to Simponi® ...
One documentmoreMedison Pharma; Alnylam Pharmaceuticals
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
Zug, Switzerland (ots/PRNewswire) - - The expanded partnership will allow Alnylam and Medison to help accelerate access for patients in multiple regions under one global alliance - Medison, the creator and leader of the multi-regional partnership category, will utilize its unique, unified platform for efficient ...
moreAdvanced Brain Science Without Coding Expertise
moreBosch Healthcare Solutions GmbH
Additional partnership in medical technology: Bosch and R-Biopharm to strengthen Vivalytic analysis platform
Darmstadt, Gerlingen, and Waiblingen, Germany (ots) - Plans to use innovative Bosch BioMEMS technology in PCR tests for multiresistant bacteria - Bosch and R-Biopharm are jointly investing 150 million euros in the development of new PCR tests and in marketing. - PCR test for multiresistant gram-negative (MRGN) ...
moreAsthma in Children: Researchers Envision Novel Drug to Reduce the Risk of the Disease
Asthma in Children: Researchers Envision Novel Drug to Reduce the Risk of the Disease Scientists have reached a milestone in the research of childhood asthma. For the first time, they have clarified how a certain genetic defect in children initially leads to frequent infections and later to asthma. The study, published in the American Journal of Respiratory and ...
moreTechnische Universität München
Boron deficiency: oilseed rape reacts as with infection and pest infestation | Genetic mechanisms uncovered
TECHNICAL UNIVERSITY OF MUNICH PRESS RELEASE Genetic mechanisms uncovered Boron deficiency: oilseed rape reacts as with infection and pest infestation - Oilseed rape reacts to boron deficiency during flowering in a similar way as to pests and infections - Boron deficiency could become an increasing problem due to ...
moreBosch Healthcare Solutions GmbH
Bosch and Randox: Strategic partnership brings highly multiplexing PCR to the point of care / BioMEMS technology enables fully automated, simultaneous testing for hundreds of genetic characteristics in just a few minutes
Waiblingen (ots) - - Bosch and Randox Laboratories Ltd. enter partnership for Vivalytic analysis platform to jointly invest around 150 million euros. - First test to feature novel BioMEMS technology will be a highly multiplexing sepsis IVD grade test. Bosch has agreed on a strategic partnership with Randox ...
moreScientists Reveal Adipocyte's Metabolic Role and Identify Treatment Targets
more- 4
FDX Fluid Dynamix and Fraunhofer IPK to Collaborate with Lonza on Novel Nanoparticle Formulation Technology Platform FDmiX
more Research Success in Rare Disease / RHEACELL receives positive signal for accelerated stem cell development program in rare ‚Butterfly Disease‘
moreRising Focus on 'Inceptor' as a Type 2 Diabetes Therapeutic Target
moreWhat Our Genetic Information Tells Us About Type 2 Diabetes Risk and Complications
moreStrengthening the Direct Sales and Service System for Business Expansion in Italy
One documentmoreBiomay Announces its Successful Support of Approval of First CRISPR/Cas9-based Therapy
moreMedison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries
Zug, Switzerland (ots/PRNewswire) - - Libtayo (cemiplimab) is a leading PD-1 inhibitor that has shown efficacy in the treatment of certain patients with cutaneous squamous cell carcinoma, advanced basal cell carcinoma, advanced non-small cell lung cancer and advanced cervical cancer, and is approved by regulatory ...
moreCells of the Future: A Key To Reprogramming Cell Identities
moreNew Source of Stem Cells in Injury-Affected Brains of Patients
moreFraunhofer-Institut für Produktionstechnologie IPT
Pooling expertise: Fraunhofer IPT and Harro Höfliger cooperate in the manufacturing of ATMP production systems
moreBiomay Announces Expansion of GMP-Facilities to Offer mRNA Manufacturing and Aseptic Filling Services
moreTechnische Universität München
Start-up dedicated to developing new antibiotics
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE Smartbax nominated for Falling Walls award Start-up dedicated to developing new antibiotics • New approach against resistant pathogens • Agent damages protein transport and energy balance of bacteria • Two TUM spin-offs nominated for Science Breakthrough of the Year at Falling Walls Summit It all began with basic research: While conducting laboratory experiments, a team ...
moreInterpreting Large-Scale Medical Datasets: ScPoli Enables Multi-Scale Representations of Cells and Samples
The increasing amount of data recorded in medical research can only lead to scientific breakthroughs and essential therapies for patients if interpreted and analyzed correctly. Computer scientists at Helmholtz Munich developed a generative model named scPoli (single-cell population level integration), that performs ...
morePress Release: Exercise and Muscle Regulation: Implications for Diabetes and Obesity
How do our muscles respond at the molecular level to exercise? Researchers at Helmholtz Munich and the German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE) have unraveled the cellular basis and signaling pathways responsible for the p ositive impact of physical activity ...
moreA New Ally in Fighting Brain Diseases: Our Very Own Skull
moreWildDISCO: Visualizing Whole Bodies in Unprecedented Detail
morePotentiating Cancer Vulnerability to Ferroptosis: Off-Targeting Effects of DHODH Inhibitors
more
1234567Next